Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer.

Tytuł:
High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer.
Autorzy:
Mollavelioglu B; Istanbul Faculty of Medicine, Department of General Surgery, Istanbul University, Istanbul, Turkey.
Cetin Aktas E; Department of Immunology, Istanbul University, Aziz Sancar Institute of Experimental Medicine, Istanbul, Turkey.
Cabioglu N; Istanbul Faculty of Medicine, Department of General Surgery, Istanbul University, Istanbul, Turkey.
Abbasov A; Istanbul Faculty of Medicine, Department of General Surgery, Istanbul University, Istanbul, Turkey.
Onder S; Department of Pathology, Istanbul University Istanbul Faculty of Medicine, Istanbul, Turkey.
Emiroglu S; Istanbul Faculty of Medicine, Department of General Surgery, Istanbul University, Istanbul, Turkey.
Tükenmez M; Istanbul Faculty of Medicine, Department of General Surgery, Istanbul University, Istanbul, Turkey.
Muslumanoglu M; Istanbul Faculty of Medicine, Department of General Surgery, Istanbul University, Istanbul, Turkey.
Igci A; Istanbul Faculty of Medicine, Department of General Surgery, Istanbul University, Istanbul, Turkey.
Deniz G; Department of Immunology, Istanbul University, Aziz Sancar Institute of Experimental Medicine, Istanbul, Turkey.
Ozmen V; Istanbul Faculty of Medicine, Department of General Surgery, Istanbul University, Istanbul, Turkey. .
Źródło:
World journal of surgical oncology [World J Surg Oncol] 2022 Oct 21; Vol. 20 (1), pp. 349. Date of Electronic Publication: 2022 Oct 21.
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Original Publication: London : BioMed Central, 2003-
MeSH Terms:
Lymphocytes, Tumor-Infiltrating*
Breast Neoplasms*/pathology
Humans ; Female ; CTLA-4 Antigen ; Hepatitis A Virus Cellular Receptor 2/metabolism ; Programmed Cell Death 1 Receptor ; Ki-67 Antigen/metabolism ; Receptors, Immunologic/metabolism ; Tumor Microenvironment
References:
Nat Med. 2016 Apr;22(4):433-8. (PMID: 26901407)
Int J Mol Sci. 2021 Aug 30;22(17):. (PMID: 34502325)
Front Immunol. 2015 Aug 21;6:418. (PMID: 26347741)
Ann Oncol. 2017 Dec 01;28(12):2977-2984. (PMID: 29045526)
Oncoimmunology. 2018 Nov 10;8(2):e1542918. (PMID: 30713804)
Biosci Rep. 2020 Jul 31;40(7):. (PMID: 32602545)
Mol Cancer. 2019 Nov 6;18(1):155. (PMID: 31690319)
J Clin Invest. 2019 Nov 1;129(11):4992-5004. (PMID: 31609250)
Front Immunol. 2019 Aug 21;10:1999. (PMID: 31552017)
Proc Natl Acad Sci U S A. 2017 May 9;114(19):4993-4998. (PMID: 28446615)
Eur J Immunol. 2002 Mar;32(3):634-43. (PMID: 11857337)
BMC Cancer. 2021 Apr 6;21(1):357. (PMID: 33823818)
Transl Oncol. 2021 Jan;14(1):100927. (PMID: 33157515)
Oncoimmunology. 2016 Dec 14;6(1):e1257452. (PMID: 28197375)
Breast Cancer Res. 2016 Jul 29;18(1):78. (PMID: 27473061)
Breast J. 2017 Jul;23(4):436-443. (PMID: 28079291)
Breast Cancer Res Treat. 2014 Dec;148(3):467-76. (PMID: 25361613)
Int J Cancer. 2020 Jul 15;147(2):423-439. (PMID: 31721169)
J Hematol Oncol. 2018 Mar 15;11(1):39. (PMID: 29544515)
Oncoimmunology. 2018 Aug 23;7(11):e1502128. (PMID: 30377566)
Ther Adv Med Oncol. 2020 Aug 17;12:1758835920940928. (PMID: 32874208)
Breast Cancer Res Treat. 2012 Apr;132(3):793-805. (PMID: 21562709)
Oncotarget. 2017 May 9;8(19):31347-31354. (PMID: 28430626)
Breast Cancer Res Treat. 2014 Jul;146(1):15-24. (PMID: 24842267)
PLoS One. 2016 Apr 13;11(4):e0152500. (PMID: 27073890)
J Immunol. 2000 Apr 1;164(7):3543-53. (PMID: 10725709)
Cancer Sci. 2017 Jan;108(1):81-90. (PMID: 27801993)
Front Immunol. 2020 Feb 13;11:167. (PMID: 32117298)
Nat Immunol. 2005 Dec;6(12):1245-52. (PMID: 16286920)
Clin Epigenetics. 2018 Jun 15;10:78. (PMID: 29983831)
Nat Immunol. 2018 Dec;19(12):1415-1426. (PMID: 30349037)
Cancer Discov. 2017 Oct;7(10):1098-1115. (PMID: 28652380)
Mol Clin Oncol. 2017 Oct;7(4):557-563. (PMID: 28855989)
BMC Cancer. 2017 Oct 17;17(1):690. (PMID: 29041905)
Neoplasma. 2021 Sep;68(5):1079-1090. (PMID: 34097428)
Histopathology. 2011 Jun;58(7):1107-16. (PMID: 21707712)
Nat Rev Cancer. 2012 Mar 22;12(4):252-64. (PMID: 22437870)
J Breast Cancer. 2018 Dec;21(4):406-414. (PMID: 30607162)
Front Immunol. 2017 Oct 30;8:1412. (PMID: 29163490)
PLoS One. 2012;7(2):e30852. (PMID: 22347406)
Cancers (Basel). 2021 Aug 17;13(16):. (PMID: 34439285)
Breast Cancer Res. 2012 Mar 15;14(2):R48. (PMID: 22420471)
Clin Exp Immunol. 2020 May;200(2):108-119. (PMID: 31828774)
Contributed Indexing:
Keywords: CTLA-4; Early-stage breast cancer; LAG-3; NK; PD-1; TIGIT; TIL; TIM-3
Substance Nomenclature:
0 (CTLA-4 Antigen)
0 (Hepatitis A Virus Cellular Receptor 2)
0 (Programmed Cell Death 1 Receptor)
0 (Ki-67 Antigen)
0 (Receptors, Immunologic)
0 (TIGIT protein, human)
Entry Date(s):
Date Created: 20221022 Date Completed: 20221025 Latest Revision: 20221025
Update Code:
20240105
PubMed Central ID:
PMC9587596
DOI:
10.1186/s12957-022-02810-z
PMID:
36271406
Czasopismo naukowe
High expression of immune checkpoint receptors (ICRs) in the tumor microenvironment regulates the anti-tumor response. In this study, the differential expressions of ICRs on tumor-infiltrating lymphocytes (TILs) in patients with early-stage breast cancer were investigated.The study included 32 patients who underwent surgery with a diagnosis of early-stage breast cancer between September 2018 and March 2020. TIL isolation was performed using a MACS tumor separation device and tumor separation kit. PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT expression of cytotoxic T and natural killer (NK) cells on TILs and peripheral blood lymphocytes (PBLs) were determined by flow cytometry.Patients with a high Ki-67 index, high TIL density, and HER-2 positivity were more likely to have increased CD16 + CD56 dim NK cells on TILs. Patients with T2 tumors were more likely to have increased expression of PD-1, LAG-3, and TIGIT on tumor-infiltrating CD8 + cytotoxic T cells than those with T1 tumors. PD-1, CTLA-4, TIGIT, LAG-3, and TIM-3 expression of CD8 + T and CD16 - CD56 bright NK cells in TILs showed significant positive correlations with each other. PD1 + CD8 + , TIGIT + CD16 + , and CTLA-4 + CD56 + cells in PBLs and TILs were found to be negatively correlated, whereas only TIM-3 + expression of CD8 + T and CD16 + CD56 dim cells in PBLs and TILs showed positive correlations.Our results suggest that CD16 + CD56 dim NK cells on TILs may play a major role in the immune response against HER2-positive or highly proliferating breast tumors in patients with early-stage breast cancer. Furthermore, various ICRs were found to be highly co-expressed with each other on TILs, including PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT. These receptors may synergistically suppress the response to the tumor, which may trigger immune escape mechanisms in the early stage of carcinogenesis. However, ICR expressions other than TIM3 on PBLs were not found to accompany their counterparts on TILs.
(© 2022. The Author(s).)
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies